{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:13:23Z","timestamp":1788484403565,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA134274"],"award-info":[{"award-number":["P30CA134274"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024327","name":"Maryland Department of Health","doi-asserted-by":"publisher","award":["CH-649-CRF"],"award-info":[{"award-number":["CH-649-CRF"]}],"id":[{"id":"10.13039\/100024327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218733","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:48:10Z","timestamp":1784962090000},"page":"218733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["GSTT1 promotes stemness and FGFR inhibitor sensitivity in pancreatic cancer through regulation of CD133 (PROM1)"],"prefix":"10.1016","volume":"658","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5654-4863","authenticated-orcid":false,"given":"Deborah","family":"de la Caridad Delgado Herrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6096-2573","authenticated-orcid":false,"given":"Alejandro Arroyo","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyan N.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lasse-Opsahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8038-9727","authenticated-orcid":false,"given":"Carrie","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sadzewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Tallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana J.","family":"Fertig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8651-9154","authenticated-orcid":false,"given":"Christina M.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10039","key":"10.1016\/j.canlet.2026.218733_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.canlet.2026.218733_bib47","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"19","key":"10.1016\/j.canlet.2026.218733_bib6","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.canlet.2026.218733_bib16","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"Hidalgo","year":"2010","journal-title":"Pancreatic cancer. N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.canlet.2026.218733_bib2","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1158\/1078-0432.CCR-13-2947","article-title":"CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide","volume":"20","author":"Banerjee","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2026.218733_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","article-title":"Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer","volume":"1","author":"Hermann","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.canlet.2026.218733_bib27","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","article-title":"Identification of pancreatic cancer stem cells","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2026.218733_bib43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.pan.2016.04.004","article-title":"The ever-changing landscape of pancreatic cancer stem cells","volume":"16","author":"Sancho","year":"2016","journal-title":"Pancreatology"},{"issue":"5","key":"10.1016\/j.canlet.2026.218733_bib28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.stem.2024.04.004","article-title":"Hallmarks of cancer stemness","volume":"31","author":"Loh","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"8","key":"10.1016\/j.canlet.2026.218733_bib29","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1038\/sj.bjc.6604307","article-title":"CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer","volume":"98","author":"Maeda","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.canlet.2026.218733_bib10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/s41556-024-01426-7","article-title":"The glutathione S-transferase Gstt1 drives survival and dissemination in metastases","volume":"26","author":"Ferrer","year":"2024","journal-title":"Nat. Cell Biol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218733_bib46","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2026.218733_bib54","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(11)70257-1","article-title":"The developing cancer stem-cell model: clinical challenges and opportunities","volume":"13","author":"Vermeulen","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218733_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jbior.2019.02.001","article-title":"Pancreatic cancer tumorspheres are cancer stem-like cells with increased chemoresistance and reduced metabolic potential","volume":"72","author":"Domenichini","year":"2019","journal-title":"Adv. Bio. Regul."},{"issue":"3","key":"10.1016\/j.canlet.2026.218733_bib21","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.325","article-title":"In vitro tumorsphere formation assays","volume":"3","author":"Johnson","year":"2013","journal-title":"Bio Protoc."},{"issue":"2","key":"10.1016\/j.canlet.2026.218733_bib26","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.18632\/oncotarget.6261","article-title":"Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218733_bib57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-62703-287-2_15","article-title":"Sphere-forming assays for assessment of benign and malignant pancreatic stem cells","volume":"980","author":"Wang","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"W1","key":"10.1016\/j.canlet.2026.218733_bib45","doi-asserted-by":"crossref","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218733_bib32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-023-01867-y","article-title":"The strategies to cure cancer patients by eradicating cancer stem-like cells","volume":"22","author":"Mai","year":"2023","journal-title":"Mol. Cancer"},{"issue":"13","key":"10.1016\/j.canlet.2026.218733_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310910","article-title":"Unmasking the deceptive nature of cancer stem cells: the role of CD133 in revealing their secrets","volume":"24","author":"Pospieszna","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218733_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-4598-13-15","article-title":"CD133 facilitates epithelial-mesenchymal transition through interaction with the ERK pathway in pancreatic cancer metastasis","volume":"13","author":"Ding","year":"2014","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2026.218733_bib19","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.4252\/wjsc.v12.i11.1410","article-title":"Glutathione metabolism is essential for self-renewal and chemoresistance of pancreatic cancer stem cells","volume":"12","author":"Jagust","year":"2020","journal-title":"World J. Stem Cell."},{"issue":"1","key":"10.1016\/j.canlet.2026.218733_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53907-7","article-title":"FGF signalling in the self-renewal of colon cancer organoids","volume":"9","author":"Otte","year":"2019","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.canlet.2026.218733_bib34","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/sj.onc.1209373","article-title":"Glutathione S-transferase polymorphisms: cancer incidence and therapy","volume":"25","author":"McIlwain","year":"2006","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.canlet.2026.218733_bib48","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/antiox10050701","article-title":"Glutathione S-transferases in cancer","volume":"10","author":"Singh","year":"2021","journal-title":"Antioxidants"},{"issue":"47","key":"10.1016\/j.canlet.2026.218733_bib51","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","article-title":"The role of glutathione-S-transferase in anti-cancer drug resistance","volume":"22","author":"Townsend","year":"2003","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.canlet.2026.218733_bib38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bbrc.2020.08.075","article-title":"Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines","volume":"533","author":"Muguruma","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.canlet.2026.218733_bib30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.neo.2019.03.007","article-title":"Metformin regulates the expression of CD133 through the AMPK-CEBP\u03b2 pathway in hepatocellular carcinoma cell lines","volume":"21","author":"Maehara","year":"2019","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.canlet.2026.218733_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.canlet.2015.05.005","article-title":"Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy","volume":"364","author":"James","year":"2015","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.canlet.2026.218733_bib55","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.stem.2020.04.008","article-title":"The rational development of CD133-targeting immunotherapies for glioblastoma","volume":"26","author":"Vora","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"12","key":"10.1016\/j.canlet.2026.218733_bib17","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.canlet.2026.218733_bib24","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1535-7163.MCT-12-0995","article-title":"BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer","volume":"12","author":"Kutluk","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"issue":"5","key":"10.1016\/j.canlet.2026.218733_bib1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218733_bib41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fcell.2020.00287","article-title":"An FGFR\/AKT\/SOX2 signaling axis controls pancreatic cancer stemness","volume":"8","author":"Quan","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"6","key":"10.1016\/j.canlet.2026.218733_bib23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.cell.2016.04.033","article-title":"SIRT6 suppresses pancreatic cancer through control of Lin28b","volume":"165","author":"Kugel","year":"2016","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.canlet.2026.218733_bib44","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.stem.2017.12.009","article-title":"Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression","volume":"22","author":"Seino","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"W1","key":"10.1016\/j.canlet.2026.218733_bib35","doi-asserted-by":"crossref","first-page":"W566","DOI":"10.1093\/nar\/gkv468","article-title":"ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap","volume":"43","author":"Metsalu","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.canlet.2026.218733_bib37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1158\/1078-0432.CCR-24-2183","article-title":"Human pancreatic cancer single-cell atlas reveals association of CXCL10+ fibroblasts and basal subtype tumor cells","volume":"31","author":"Loveless","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.canlet.2026.218733_bib12","article-title":"The heterogeneity of the tumor microenvironment as essential determinant of development, progression and therapy response of pancreatic cancer","volume":"13","author":"Wandmacher","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.canlet.2026.218733_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2012.03.003","article-title":"Cancer stem cells: impact, heterogeneity, and uncertainty","volume":"21","author":"Magee","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.canlet.2026.218733_bib53","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.canlet.2026.218733_bib25","doi-asserted-by":"crossref","DOI":"10.2196\/27633","article-title":"Web-based survival analysis tool tailored for medical research (KMplot): development and implementation","volume":"23","author":"L\u00e1nczky","year":"2021","journal-title":"J. Med. Internet Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:42:22Z","timestamp":1788482542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":42,"alternative-id":["S0304383526004970"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218733","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GSTT1 promotes stemness and FGFR inhibitor sensitivity in pancreatic cancer through regulation of CD133 (PROM1)","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218733"}}